Yuan Xiangwei, Li Bin, Wang Qiaojie, Zhang Xianlong
Department of Orthopaedics, Shanghai Sixth People's Hospital, Shanghai Jiao Tong University, Shanghai, China.
J Arthroplasty. 2017 Sep;32(9):2738-2743. doi: 10.1016/j.arth.2017.03.059. Epub 2017 Apr 5.
The mode of administration for tranexamic acid (TXA) to significantly reduce the decrease in hemoglobin (Hb), number of transfusions, relevant costs, and side effects in patients undergoing primary unilateral total knee arthroplasty (TKA) has not been resolved.
A total of 560 patients undergoing primary unilateral TKA were randomized into 4 groups: intravenous group (140 patients receiving 2 doses of 20 mg/kg intravenous TXA), topical group (140 patients administered 3.0 g topical TXA), oral group (140 patients given 2 doses of 20 mg/kg oral TXA), and a control group (140 patients not given TXA). The primary outcomes included postoperative 48-hour Hb loss and drainage volume, number of transfusions, transfusion and TXA costs, and thromboembolic complications. Secondary outcomes were postoperative inpatient time and wound healing 3 weeks after TKA.
Baseline data among the 4 groups were similar. The 48-hour Hb loss and drainage volume in the intravenous, topical, and oral groups were significantly less (P < .05) than those in the control group, and the latter had significantly more transfusions and transfusion costs than the other 3 groups (P < .05). The TXA cost was lowest in the oral group compared with that in the topical and intravenous groups (P < .05). No differences in thromboembolic complications, postoperative inpatient time, or wound healing were observed among the groups. However, wound dehiscence and continuous wound discharge occurred in the topical group.
All the 3 modes of TXA administration significantly reduced postoperative Hb loss, the number of transfusions, and transfusion costs compared with those in the control group. No pulmonary embolism or infection was observed. Oral TXA is recommended because it provided a similar clinical benefit and resulted in the lowest TXA cost compared with the other 2 modes of TXA administration.
氨甲环酸(TXA)用于显著减少初次单侧全膝关节置换术(TKA)患者血红蛋白(Hb)下降、输血次数、相关费用及副作用的给药方式尚未明确。
总共560例行初次单侧TKA的患者被随机分为4组:静脉注射组(140例患者接受2剂20mg/kg静脉注射TXA)、局部应用组(140例患者给予3.0g局部应用TXA)、口服组(140例患者给予2剂20mg/kg口服TXA)和对照组(140例患者未给予TXA)。主要结局包括术后48小时Hb丢失量和引流量、输血次数、输血及TXA费用以及血栓栓塞并发症。次要结局为术后住院时间和TKA术后3周伤口愈合情况。
4组间的基线数据相似。静脉注射组、局部应用组和口服组术后48小时Hb丢失量和引流量显著少于对照组(P<.05),且对照组输血次数和输血费用显著多于其他3组(P<.05)。与局部应用组和静脉注射组相比,口服组的TXA费用最低(P<.05)。各组间在血栓栓塞并发症、术后住院时间或伤口愈合方面未观察到差异。然而,局部应用组出现了伤口裂开和伤口持续渗液的情况。
与对照组相比,所有3种TXA给药方式均显著减少了术后Hb丢失量、输血次数和输血费用。未观察到肺栓塞或感染情况。推荐口服TXA,因为与其他2种TXA给药方式相比,它提供了相似的临床获益且TXA费用最低。